166 related articles for article (PubMed ID: 34188985)
1. Mutant Phenotype p53 Immunohistochemical Expression Is Associated With Poor Prognostic Parameters and Disease-Free Survival in Triple-Negative Metaplastic Breast Carcinoma.
Hashmi AA; Sajid A; Hussain M; Zia S; Islam S; Diwan MA; Ali SM; Irfan M; Shamail F; Zia F
Cureus; 2021 May; 13(5):e15244. PubMed ID: 34188985
[TBL] [Abstract][Full Text] [Related]
2. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer.
Hashmi AA; Naz S; Hashmi SK; Hussain ZF; Irfan M; Khan EY; Faridi N; Khan A; Edhi MM
BMC Clin Pathol; 2018; 18():9. PubMed ID: 30305801
[TBL] [Abstract][Full Text] [Related]
4. Metaplastic Breast Carcinoma: Clinicopathological Parameters and Prognostic Profile.
Haroon S; Zia S; Shirazi UA; Ahmed O; Asghar IA; Diwan MA; Afzal A; Irfan M; Ali SJ; Hashmi AA
Cureus; 2021 Apr; 13(4):e14347. PubMed ID: 33987039
[TBL] [Abstract][Full Text] [Related]
5. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature.
El Zein D; Hughes M; Kumar S; Peng X; Oyasiji T; Jabbour H; Khoury T
Clin Breast Cancer; 2017 Aug; 17(5):382-391. PubMed ID: 28529029
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.
Jasar D; Smichkoska S; Kubelka K; Filipovski V; Petrushevska G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):69-79. PubMed ID: 26076776
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 and Twist1 Co-Expression Predicts Poor Prognosis and Is an Independent Prognostic Factor in Breast Cancer.
Zhang YQ; Zhang F; Zeng YZ; Chen M; Huang WH; Wu JD; Chen WL; Gao WL; Bai JW; Yang RQ; Zeng HC; Wei XL; Zhang GJ
Front Oncol; 2021; 11():628814. PubMed ID: 34249678
[TBL] [Abstract][Full Text] [Related]
8. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
9. Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity.
Lim KH; Oh DY; Chie EK; Han W; Im SA; Kim TY; Park IA; Noh DY; Ha SW; Bang YJ
Jpn J Clin Oncol; 2010 Feb; 40(2):112-8. PubMed ID: 19887523
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and Radiological Features with Long Term Follow Up of Metaplastic Carcinoma Breast in India.
Puri G; Lohani KR; Khadka S; Kataria K; Ranjan P; Hari S; Mathur S; Dhar A; Srivastava A
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3483-3492. PubMed ID: 34837903
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological Parameters and Biomarker Profile in a Cohort of Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
Hashmi AA; Bukhari U; Aslam M; Joiya RS; Kumar R; Malik UA; Zia S; Khan AR; Saleem M; Irfan M
Cureus; 2023 Jul; 15(7):e41941. PubMed ID: 37588336
[TBL] [Abstract][Full Text] [Related]
12. Mucinous Breast Carcinoma: Clinicopathological Comparison With Invasive Ductal Carcinoma.
Hashmi AA; Zia S; Yaqeen SR; Ahmed O; Asghar IA; Islam S; Afzal A; Irfan M; Zia F; Ali J
Cureus; 2021 Mar; 13(3):e13650. PubMed ID: 33824803
[TBL] [Abstract][Full Text] [Related]
13. Association of p53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma.
Qamar S; Khokhar MA; Farooq S; Ashraf S; Humayon WA; Rehman A
J Coll Physicians Surg Pak; 2019 Feb; 29(2):164-167. PubMed ID: 30700357
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype.
Tadros AB; Sevilimedu V; Giri DD; Zabor EC; Morrow M; Plitas G
Ann Surg Oncol; 2021 Aug; 28(8):4245-4253. PubMed ID: 33389291
[TBL] [Abstract][Full Text] [Related]
15. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
Li Y; Zhang N; Zhang H; Yang Q
J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
[TBL] [Abstract][Full Text] [Related]
16. Metaplastic breast cancer: Prognostic and therapeutic considerations.
Corso G; Frassoni S; Girardi A; De Camilli E; Montagna E; Intra M; Bottiglieri L; Margherita De Scalzi A; Fanianos DM; Magnoni F; Invento A; Toesca A; Conforti F; Bagnardi V; Viale G; Colleoni MA; Veronesi P
J Surg Oncol; 2021 Jan; 123(1):61-70. PubMed ID: 33047318
[TBL] [Abstract][Full Text] [Related]
17. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
18. Expression profile of tumour suppressor protein p53 and its regulator MDM2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana.
Opoku F; Bedu-Addo K; Titiloye NA; Atta Manu E; Ameh-Mensah C; Duduyemi BM
PLoS One; 2021; 16(10):e0258543. PubMed ID: 34695137
[TBL] [Abstract][Full Text] [Related]
19. Metaplastic carcinoma of the breast: an immunohistochemical study.
Altaf FJ; Mokhtar GA; Emam E; Bokhary RY; Mahfouz NB; Al Amoudi S; Al-Gaithy ZK
Diagn Pathol; 2014 Jul; 9():139. PubMed ID: 25030022
[TBL] [Abstract][Full Text] [Related]
20. Descriptive study of the histopathological subtypes and programmed death-ligand 1 in metaplastic breast carcinoma.
Stephen N; Jinkala S; Ch Toi P; Ganesh RN; Bheemanathi Hanuman S; Badhe BA; Gochhait D; Dubashi B
Breast J; 2020 Dec; 26(12):2371-2375. PubMed ID: 32959535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
